BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharm Res 2022. [PMID: 35650449 DOI: 10.1007/s11095-022-03302-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Sadek MA, Kandil EA, El Sayed NS, Sayed HM, Rabie MA. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway. Int Immunopharmacol 2022;115:109647. [PMID: 36584570 DOI: 10.1016/j.intimp.2022.109647] [Reference Citation Analysis]
2 Lee WL, Wang PH, Yang ST, Liu CH, Chang WH, Lee FK. To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases. J Chin Med Assoc 2022;85:1109-19. [PMID: 36279128 DOI: 10.1097/JCMA.0000000000000831] [Reference Citation Analysis]
3 Du H, Meng X, Yao Y, Xu J. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease. Front Endocrinol (Lausanne) 2022;13:1033479. [PMID: 36465634 DOI: 10.3389/fendo.2022.1033479] [Reference Citation Analysis]
4 Gangopadhyay A, Ibrahim R, Theberge K, May M, Houseknecht KL. Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines. Front Neurosci 2022;16. [DOI: 10.3389/fnins.2022.1042442] [Reference Citation Analysis]